BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (OTCQX:BLGO) announced a breakthrough upgrade to its patented Aqueous Electrostatic Concentrator (AEC) that cuts energy use by more than 90% for large-scale PFAS treatment versus prior AEC generations. The company cites prior May 2025 data showing up to 80% total life-cycle cost savings versus carbon technologies and claims non-detect PFAS removal <1 ppt in drinking and brackish water.
Example: a 1,000 gpm municipal system could see monthly energy costs fall from ~$208,000 to ~$15,700 (>$2.3M annual savings at $0.15/kWh). An industrial test showed 88% energy reduction; waste is reported as 1/40,000th that of carbon systems. A first commercial installation in New Jersey is nearing operation.
BioLargo (OTCQX: BLGO) announced that its CEO presented at the LD Micro Main Event XIX on October 20, 2025 at the Hotel del Coronado in San Diego.
The presentation covered Cellinity battery cell technology, BioLargo’s role in the global AI infrastructure investment cycle, and a general corporate update. The company filed a Form 8-K on October 20, 2025 to provide the presentation materials, which are available online at the company’s SEC filings page: https://www.biolargo.com/sec-filings.
BioLargo (OTCQX:BLGO) invites professionals to the 16th Annual Sustain SoCal Energy Event on October 16, 2025 at The Cove at UCI Beall Applied Innovation in Irvine, CA.
The full-day conference, themed "Energy in Perspective," runs 9:00 AM–7:00 PM and features a keynote by David Hayes, discussions on nuclear energy, hydrogen, AI-driven residential engagement, local energy programs, and the 2025 Sustainability Awards.
BioLargo is a sponsor and speaker and will highlight its #Cellinity battery technology for grid-scale energy storage. Registration and event details are available on the Sustain SoCal event page.
BioLargo (OTCQX:BLGO) will present its Cellinity battery technology at LD Micro Main Event XIX on Monday, October 20, 2025 at 2:00 p.m. PT at the Hotel del Coronado in San Diego.
Management says Cellinity is a battery storage solution for AI infrastructure that eliminates the need for rare earth elements. The company emphasizes applications in AI data centers and grid-scale storage and notes related capabilities in water reuse, PFAS remediation, odor/VOC control, and on-site energy storage. A live webcast is available at https://ldmicrocasts.com/#register.
The release includes a Safe Harbor statement about forward-looking expectations and refers investors to the company's SEC filings for risks.
BioLargo (OTCQX:BLGO) announced that its subsidiary Clyra Medical is advancing toward commercial launches and international expansion for its ViaCLYR wound irrigation and surgical products, targeting initial U.S. and select EMEA sales in late 2025 or early 2026. Key activities include distributor agreements for EMEA and U.S. reach, completion of package and label design, product claim finalization, and ongoing stability, packaging and process validation ahead of standard FDA submission and review. Clyra has secured $7.5 million in capital to support manufacturing readiness and rollouts. Market context cites a $732 million 2024 wound irrigation market with 3.4% CAGR to 2034.
Summary not available.
BioLargo (OTCQX:BLGO) has achieved a significant breakthrough in PFAS treatment technology, demonstrating that its proprietary Aqueous Electrostatic Concentration (AEC) solution can remove over 99% of ultrashort-chain PFAS, including trifluoroacetic acid (TFA).
The company's technology effectively captures and eliminates TFA, a persistent contaminant found in industrial processes that accounts for over 90% of total PFAS mass in various drinking water sources. The AEC system uses electrostatic forces to selectively attract and isolate charged contaminants, followed by a proprietary destruction technique, without generating harmful byproducts or secondary waste streams.
BioLargo is currently deploying the technology commercially in North America and is in discussions with potential partners and customers for expanded commercial activities.
BioLargo (OTCQX:BLGO) announced its participation in WEFTEC 2025, North America's largest water quality event, where it will showcase its innovative PFAS remediation and odor control solutions at Booth #6009 from September 29 to October 1 in Chicago.
The company will feature its Aqueous Electrostatic Concentration (AEC) Solution, designed to efficiently remove and destroy various PFAS compounds, and CupriDyne® Clean, their patented odor and VOC control technology. Additionally, Verralize will demonstrate its PFAS Field Test Kits at BioLargo's booth, offering rapid on-site PFAS contamination detection capabilities.
BioLargo (OTCQX:BLGO) has revoked Pooph Inc.'s technology license and terminated their agreement due to Pooph's failure to meet contractual obligations, including approximately $3.8 million in unpaid fees. The termination requires Pooph to immediately cease marketing and selling products incorporating BioLargo's patents and proprietary technology.
Prior to termination, Pooph had successfully leveraged BioLargo's technology to achieve over $50 million in annual sales and garnered thousands of positive customer reviews. BioLargo remains focused on advancing its technology portfolio in infection control, wound care, "forever chemicals" management, and innovative battery systems while protecting its intellectual property rights.
BioLargo (OTCQX:BLGO), a cleantech and environmental solutions company, reported its Q2 2025 financial results with revenues of $2.77 million for Q2 and $6.04 million for H1 2025. The company highlighted significant progress across multiple divisions, with its engineering segment experiencing a 517% revenue increase in air quality control services.
Notable achievements include Clyra Medical Technologies securing distribution agreements covering 6,100 hospitals and thousands of medical facilities, while the company's Cellinity battery technology received validation from U.S. BESS Corporation and secured four MOUs for potential factory partnerships. As of June 30, 2025, BioLargo maintained a strong financial position with $3.47 million in cash, total assets of $12.49 million, and stockholders' equity of $6.06 million.